TARGETED DRUG BOOSTS SURVIVAL AMONG LIVER CANCER PATIENTS: "The drug Nexavar can prolong the lives of people with liver cancer by an average of three months, new research shows.
'The results unequivocally showed that sorafenib (Nexavar) increased the survival of patients with a more than 30 percent reduction in the likelihood to die at any time point during follow-up,' said study senior author Dr. Jordi Bruix, a senior consultant in the liver unit of the Hospital Clinic of Barcelona.
'These results identify sorafenib as the first agent that is effective in improving survival in patients with this devastating disease,' said Bruix. His report is in the July 24 issue of the New England Journal of Medicine."
Friday, 25 July 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment